FDA 483 - Bora Pharmaceuticals Inc. - July 11, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Upsher Smith Laboratories, LLC in Maple Grove, MN, revealed significant deficiencies in their manufacturing processes. Observations included inadequate testing of drug product components for harmful substances like diethylene glycol, and failure to follow written procedures for equipment cleaning and maintenance. Additionally, the firm's batch records lacked proper documentation for equipment identification, indicating a lack of control over critical aspects of drug manufacturing and quality.
ID · e63189c9-733c-4474-89cc-4dcea8d6dfe6